A new study finds that ursodeoxycholic acid (UDCA) effectively dissolves gallstones in 60% of patients after sleeve ...

Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...

While UDCA remains the standard-of-care treatment in PBC, challenges to care revolve around treatment access and resistance. Ursodeoxycholic acid (UDCA) has remained the first-line treatment for ...

The company's Investigational New Drug, Nor Ursodeoxycholic Acid (Nor UDCA), has received the green light from the Subject Expert Committee of CDSCO for treating NAFLD. NAFLD affects 25% of the global ...

综上所述，这项研究表明，熊去氧胆小檗碱在降低2型糖尿病患者的血糖水平、改善血脂状况以及潜在的肝脏保护方面显示出巨大潜力。这一发现为未来 糖尿病 管理提供了新的治疗选择，值得进一步深入研究和应用。

研究人员运用了多种关键技术方法。在纳米囊泡制备方面，通过超声破碎 RAW264.7 细胞，再经一系列处理得到巨噬细胞来源的纳米囊泡（NVs），并将 UDCA 载入其中，进一步修饰得到线粒体靶向的纳米囊泡（UDCA-NVs-TPP） 。在细胞和动物实验中，利用多种细胞模型和 PD 小鼠模型，借助 CCK-8、ABTS ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the ...

Hepatocellular DILI is characterized by inflammation, necrosis, and apoptosis, while cholestatic DILI involves bile plug formation and bile duct paucity. Ursodeoxycholic acid (UDCA), a widely used ...

近日，吉利德宣布，欧盟委员会（EC）已有条件批准Seladelpar上市，与熊去氧胆酸（UDCA）联用，治疗对UDCA单药应答不足的原发性胆汁性胆管炎（PBC）患者；或者作为单药，治疗对UDCA治疗不耐受的PBC患者。

Ursodeoxycholic acid (UDCA) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies of diverse etiologies and has been mainly used as a supportive treatment in ...

【适应症】 无肝硬化或无门脉高压证据的代偿性肝硬化的原发性胆汁性胆管炎 (PBC)，对于对 UDCA 反应不足的成人，与熊去氧胆酸 (UDCA) 联合使用，或作为无法耐受 UDCA 的成人的单一疗法。 最初每天一次 5 毫克；如果 3 个月后 ALP 和/或总胆红素下降幅度不大且耐受 ...